Research: Making the biotech IPO work
There were more biotech IPOs in 2012-13 than in a y previous IPO window. Will these companies be able to deliver of their promise of new generations of therapeutic products and economic growth? A recent paper from the Center for Integration of Science and Industry provides a prescription for success that will require strategic business models and patience. Listen to interview on Bloomberg Radio.
Research: What was the value of Human Genome Science?
When Human Genome Sciences (HGS) was acquired by GlaxoSmithKline (GSK) in 2012, its “fair value” was $3.6B, less than the $3.9B capital investments in the company. Does this truly reflect the value of a product (BenlystaTM) with billion-dollar potential, HGS’ product pipeline, and >600 patents? A recent paper from the Center for Integration of Science and Industry reviews the history of HGS and valuation of HGS and argues that there is a need for greater alignment between the milestones of translational science and measures of corporate value.
Research: Can newly-public biotech succeed at translational science? by Laura McNamee and Fred Ledley
Early-stage biotech companies play a critical role in the entrepreneurial ecosystem that is expected to develop commercial products from nascent scientific discoveries. Recent research from the Center for Integration of Science and Industry suggests that companies in the IPO “class of 2000” were ineffective in developing therapeutic products and asks whether the business models of newly-public biotech companies are up to the task.
Research: Are there patterns to successful biotech innovation?
Innovation in biotechnology is often portrayed as being wildly complex and unpredictable. Recent research from the Center for Integration of Science and Industry suggests that there are patterns in the timelines of technological maturation and successful development of therapeutic biotechnologies that are predictable from innovation theory.
Research: Why commercialization of gene therapy stalled
It has been 40 years since recombinant technologies first enabled consideration of gene therapy for human disease, and 30 years since the first gene therapy companies were formed. Yet, there are no gene therapies on the market in the US or EU. A recent research paper from the Center for Integration of Science and Industry explores how asynchrony between capital investments and the maturation of gene therapy technologies may have contributed to this delay.